Selective Protection of Human Liver Tissue in TNF-Targeting of Cancers of the Liver by Transient Depletion of Adenosine Triphosphate

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Weiland, Timo ^a   Klein, Kathrin ^b   Zimmermann, Martina ^a   Speicher, Tobias ^c   Venturelli, Sascha ^a   Berger, Alexander ^a   Bantel, Heike ^d   Königsrainer, Alfred ^a   Schenk, Martin ^a   Weiss, Thomas S ^e   Wendel, Albrecht ^f   Schwab, Matthias ^a,b   Bitzer, Michael ^a   Lauer, Ulrich M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c ETH ZURICH   (Switzerland)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; FRUCTOSE; HEXOKINASE; HEXOKINASE ISOENZYME; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBOHYDRATE METABOLISM; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; ENZYME SPECIFICITY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CANCER; LIVER CELL; LIVER PROTECTION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE SECTION;

ADENOSINE TRIPHOSPHATE; CELL DEATH; CELL LINE, TUMOR; CELLS, CULTURED; FRUCTOSE; HEPATOCYTES; HEXOKINASE; HUMANS; LIVER; LIVER NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 84871310412     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052496     Document Type: Article

References (21)

1. Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, et al. (1988) Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 80: 1039-1044.
2. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E 3rd, et al (1988) Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 6: 344-350.
3. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ, (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52-60.
4. Lejeune F, Liénard D, Eggermont A, Schraffordt Koops H, Rosenkaimer F, et al. (1994) Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma. J Cell Biochem 56: 52-61.
5. Christoforidis D, Martinet O, Lejeune F, Mosimann F, (2002) Isolated liver perfusion for non-resectable liver tumours: a review. Eur J Surg Oncol 28: 875-890.
6. de Vries MR, Borel Rinkes IH, van de Velde CJ, Wiggers T, Tollenaar RA, et al. (1998) Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res 147: 107-119.
7. Alexander HR, Brown CK, Bartlett DL, Libutti SK, Figg WD, et al. (1998) Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. Clin Cancer Res 4: 2357-2362.
8. Weinreich DM, Alexander HR, (2002) Transarterial perfusion of liver metastases. Semin Oncol 29: 136-144.
9. Latta M, Kunstle G, Leist M, Wendel A, (2000) Metabolic depletion of ATP by fructose inversely controls CD95- and tumor necrosis factor receptor 1-mediated hepatic apoptosis. J Exp Med 191: 1975-1985.
10. Speicher T, Foehrenbacher A, Pochic I, Weiland T, (2010) Malignant but not naïve hepatocytes of human and rodent origin are killed by TNF after metabolic depletion of ATP by fructose. J Hepatol. 53: 896-902.
11. Woods HF, Eggleston LV, Krebs HA, (1970) The cause of hepatic accumulation of fructose 1-phosphate on fructose loading. Biochem J (119):: 501-510.
12. Speicher T, Koehler UA, Chouker A, Werner S, Weiland T, et al. (2012) Fructose protects murine hepatocytes from TNF-induced apoptosis by modulating JNK signaling. J Biol Chem 287: 1837-1846.
13. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, et al. (1999) Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 282: 1659-1664.
14. Terrier F, Vock P, Cotting J, Ladebeck R, Reichen J, et al. (1989) Effect of intravenous fructose on the P-31 MR spectrum of the liver: dose response in healthy volunteers. Radiology (171):: 557-563.
15. Boesch C, Elsing C, Wegmüller H, Felblinger J, Vock P, et al. (1997) Effect of ethanol and fructose on liver metabolism: a dynamic 31Phosphorus magnetic resonance spectroscopy study in normal volunteers. Magn Reson Imaging. 15: 1067-1077.
16. Oberhaensli RD, Galloway GJ, Taylor DJ, Bore PJ, Radda GK, (1986) Assessment of human liver metabolism by phosphorus-31 magnetic resonance spectroscopy. Br J Radiol (59):: 695-699.
17. Boesiger P, Buchli R, Meier D, Steinmann B, Gitzelmann R, (1994) Changes of liver metabolite concentrations in adults with disorders of fructose metabolism after intravenous fructose by 31P magnetic resonance spectroscopy. Pediatr Res 36: 436-440.
18. Kim JW, Dang CV, (2006) Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66: 8927-8930.
19. Leist M, Gantner F, Bohlinger I, Germann PG, Tiegs G, et al. (1994) Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. J Immunol 153: 1778-1788.
20. Hentze H, Latta M, Künstle G, Dhakshinamoorthy S, Ng PY, et al. (2004) Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis. Hepatology. 2004 39: 1311-1320.
21. Zimmermann M, Armeanu S, Smirnow I, Kupka S, Wagner S, et al. (2009) Human Precision Cut Liver Tumor Slices as a comprehensive predictive test system for the oncolytic effectiveness of measles vaccine viruses; Int J Oncol. 34: 1247-1256.